[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mesothelioma-lung\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mesothelioma-lung":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,61,90,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":42,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100437810","solid-tumor-analysis-for-hla-loss-of-heterozygosity-loh-and-apheresis-for-car-t--cell-manufacturing-100437810",false,"NCT04981119","Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing","An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing","BASECAMP-1","Key Eligibility Criteria (additional criteria may apply) Part 1 Key Inclusion Criteria\n\n1\\. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), or Pancreatic Cancer (PANC), that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years.\n\nPart 1: Key Exclusion Criteria\n\n1. History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.\n2. Prior allogeneic stem cell transplant.\n3. Prior solid organ transplant.\n\nPart 2 : Key Inclusion Criteria\n\n1. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PANC), Mesothelioma, or Ovarian Cancer (OVAC) that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years.\n2. Participants are germline HLA-A\\*02 heterozygous confirmed by HLA typing.\n3. Primary tumor tissue showing LOH of HLA-A\\*02 by NGS testing.\n4. Eastern Cooperative Oncology Group (ECOG) 0 or 1 performance status.\n\nPart 2: Key Exclusion Criteria\n\n1. History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.\n2. Prior allogeneic stem cell transplant.\n3. Prior solid organ transplant.\n4. Participants who have received any cancer therapy on any investigational therapy for any indication, including but not limited to chemotherapy, small molecules, monoclonal antibodies, or radiotherapy (with bone marrow impact) within 2 weeks of planned apheresis or 3 half-lives, whichever is shorter.\n5. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment necessitating specific treatment, or any major episode of infection requiring treatment with Intravenous (IV) antimicrobials (e.g., IV antibiotics) or hospitalization (relating to completion of antibiotic course).\n6. Has known active central nervous system metastases. Subjects with previously treated brain metastases may participate upon medical monitor agreement.\n7. In the Investigator's judgement, any other condition or reason the subject would not complete the required study visits and procedures, and follow up visits, or comply with the study requirements for participation.","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","Objective:\n\nTo collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment.\n\nDesign:\n\nThis is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Solid Tumor, Adult","Colorectal Cancer","Non Small Cell Lung Cancer","Pancreatic Cancer","CRC","NSCLC","Pancreas Cancer","Mesothelioma","Ovarian Cancer","Ovarian Neoplasms","Ovarian Carcinoma","Mesothelioma, Malignant","Mesothelioma; Lung","Cancer","Triple Negative Breast Cancer (TNBC)","Renal Cell Carcinoma (Kidney Cancer)","Head and Neck Squamous Cell Carcinoma HNSCC",[43,44,45,46,47],"CAR T Cell Therapy","Next Generation Sequencing","Leukapheresis","Apheresis","Immunotherapy","RECRUITING","2026-05-29",{"date":51,"type":52},"2026-06-02","ACTUAL",{"date":54,"type":52},"2021-10-29",{"date":56,"type":21},"2029-04",{"name":58,"class":59},"A2 Biotherapeutics Inc.","INDUSTRY",16,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100602668","partial-pleurectomy-surgery-for-unresectable-pleural-mesothelioma-100602668","NCT07126509","Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma","A Pilot Study of Partial Pleurectomy in Borderline and Unresectable Pleural Mesothelioma","Inclusion Criteria\n\n* Patients must have histologically confirmed epithelioid subtype pleural mesothelioma, as determined by surgical (i.e. VATS) biopsy.\n* Disease confined to the unilateral hemithorax.\n* Disease that is classified as unresectable or borderline resectable:\n* Unresectable disease is defined by cross sectional imaging (CT or MRI) demonstrating invasion of unresectable mediastinal structures (heart, great vessels, esophagus) or spine, unresectable invasion of the chest wall (multifocal chest wall invasion or apical chest wall invasion), or disease outside intended resection field.\n* Borderline resectable disease is defined by cross sectional imaging (CT or MRI) demonstrating extensive pulmonary parenchymal invasion (anticipated need for anatomic resection or complex wedge resection to clear disease) or extensive\u002Fbulky disease of (1) the diaphragm or sulci (anticipated need for diaphragm resection and reconstruction to clear disease), or (2) the chest wall (anticipated need for chest wall resection and reconstruction to clear disease). Disease with pathologically proven hilar or mediastinal lymph node involvement.\n* Successful completion of at least 6 weeks of systemic induction therapy (regimen according to treating physician choice, including the below) with no unresolved adverse event that would preclude surgery:\n* Platinum agent, pemetrexed, +\u002F- bevacizumab\n* Platinum agent, pemetrexed, pembrolizumab\n* Ipilimumab\u002Fnivolumab\n* Age ≥18 years.\n* ECOG performance status ≤1.\n* Patients must have adequate organ and marrow function as defined below:\n\n  * leukocytes ≥3,000\u002FmcL\n  * absolute neutrophil count ≥1,500\u002FmcL\n  * platelets ≥100,000\u002FmcL\n  * PT\u002FINR \\>1.5\n  * PTT \\>Upper limit of normal\n  * total bilirubin within normal institutional limits\n  * AST(SGOT)\u002FALT(SGPT) ≤2.5 × institutional upper limit of normal\n  * creatinine within normal institutional limits OR\n  * creatinine clearance ≥60 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional normal.\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification21. To be eligible for this trial, patients should be class 2B or better.\n* Review by multidisciplinary treatment conference consisting of mesothelioma surgeons, radiologists, pathologists, medical oncologists, and palliative care physicians. Date of review will be documented in on the patient's elgibility checklist\n* Prior or concurrent enrollment to UChicago's Mesothelioma Biobank (IRB15-0443).\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria\n\n* Patients with biphasic or sarcomatoid pleural mesothelioma.\n* Patients with metastatic disease or disease which extends to the abdominal cavity or subdiaphragm as identified on post-induction therapy cross sectional imaging (CT, MRI, or PET).\n* Patients who demonstrate disease progression during or following induction therapy.\n* FEV1 \\\u003C 50% and\u002For postoperative predicted DLCO \\\u003C 50%.\n* Patients who are receiving any other investigational agents.\n* Patients with uncontrolled intercurrent illness.\n* Prior malignancy active 2 years prior to registration except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast, or papillary thyroid.",{"count":69,"type":21},30,"INTERVENTIONAL",[72],"NA","Purpose of the study: The main purpose of this research study is to see if a surgery procedure (limited partial pleurectomy and decortication) helps symptoms in people who have cancer that is unresectable that might not be able to be removed completely. This is called unresectable cancer. This study will also help the research team learn more about the types of symptoms and quality of life for people who have undergone this surgery, the number of complications following , and the time from surgery to starting other therapy. Th e study team also wants to see see the overall survival of people who have had this procedure as part of their care.\n\nWhat will be done as part of research on this study:\n\n* Surgery (Partial Pleurectomy - surgery to remove lining of lungs)\n* The research team will also ask study participants questions about their symptoms through questionnaires at certain times after surgery.\n\nHow long this study will last:\n\nParticipation in this research (pre-surgery, surgery and follow-up) will last for about 2 years.\n\nConfidentiality: All personal information will be kept confidential, and data will be used only for research purposes.\n\nContact Information: For more information about this study, please contact PhaseIICRA@medicine.bsd.uchicago.edu",[32,37,75,76,36],"Mesotheliomas Pleural","Mesothelioma Malignant Advanced",[78],"PLEURECTOMY","2026-02-13",{"date":81,"type":52},"2026-02-17",{"date":83,"type":52},"2025-12-02",{"date":85,"type":21},"2028-12-01",{"name":87,"class":88},"University of Chicago","OTHER",1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100560776","immune-microenvironment-and-gene-expression-profiling-in-mesothelioma-100560776","NCT06581549","Immune Microenvironment and Gene Expression Profiling in Mesothelioma","From Immune Microenvironment Characterization and Gene Expression Profiling to New Drugs Testing in Pleural and Peritoneal Mesothelioma: Imaging-Meso Study","Imaging-Meso","Inclusion Criteria:\n\n* Patients with Mesothelioma of the Pleura and Peritoneum\n* Age greater than 18 years of age\n* Patients undergoing surgery will require both biopsy and surgical sampling material\n* Pathologist's confirmation of the presence of tumor sections in the excised specimens\n* Patients in follow-up from active cancer treatment for at least 6 months\n\nExclusion Criteria:\n\n* Inadequacy of biological material for analysis under study\n* Patients not amenable to active oncologic treatment\n* Patients lost to follow-up before 6 months after the end of active oncologic treatment",{"count":99,"type":21},220,"Pleural and peritoneal mesotheliomas (PPM) are rare cancers mostly related to asbestos-exposure, which are characterized by a complex histopathological diagnosis and staging, few therapeutic options and a dismal prognosis. The main unmet medical need in PPM is the lack of a treatment sequence for affected patients. The advent of immune checkpoint inhibitors has changed the first line treatment of PPM, thanks to the improvement in survival achieved by the combination of ipilimumab and nivolumab that are currently approved for non-epithelioid histology in our Country.\n\nPPM is characterized by a large heterogeneity of the genomic landscape, which is mainly characterized by the loss of tumour suppressor genes and mutations in DNA repair genes and by an \"altered- suppressed\" or \"excluded\" tumor immune microenvironment (TIME).\n\nThe goal of this project is to improve the immune-biological and molecular stratification of PPM subgroups that can lead to the identification of different personalized treatment approaches. PPM patients (N=220) will be retrospectively (N=150) and prospectively (N=70) recruited from the coordinator center and 6 participating Italian centers. Treatment-naïve tumor samples will be collected and analyzed by bulk gene expression and spatial whole transcriptome analysis, and by 9-color multiplex immunofluorescence.\n\nNew targets or actionable pathways potentially emerging from such studies will be finally assessed and validated in patient-derived organoids\u002Fxenografts that accurately reflect PPM tumorigenesis.",[32,75,37],[103,104,105,106,107,108],"pleura","mesothelioma","PPM patients","lung","Gene expression profiling","Immune microenvironment","2025-09-04",{"date":111,"type":52},"2025-09-05",{"date":113,"type":52},"2023-11-02",{"date":115,"type":21},"2026-12-31",{"name":117,"class":88},"Istituto Oncologico Veneto IRCCS",10,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":70,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100539988","exercise-to-boost-immunity-in-advanced-cancer-100539988","NCT06310993","Exercise to Boost Immunity in Advanced Cancer","Exercise to Boost Immunity in Advanced Cancer: Feasibility of Combined Aerobic Exercise and Resistance Training for Patients with Advanced Mesothelioma and Pancreatic Cancer","BICEP","Inclusion Criteria:\n\n* Patients about to start or who are undergoing first line palliative immunotherapy for advanced, unresectable, or metastatic mesothelioma or patients about to start or who are undergoing first line palliative chemotherapy for advanced, unresectable, or metastatic pancreatic cancer.\n* Age over 18 years old\n* Histological or cytological diagnosis of mesothelioma or pancreatic cancer.\n* ECOG Performance status 0-1 (to be assessed by clinician)\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Prior treatment with systemic anti-cancer treatment\n* More than one primary cancer\n* Uncontrolled brain or bone metastases\n* Patients who have progressed on first line palliative immunotherapy for advanced, unresectable, or metastatic mesothelioma.\n* Patients who have progressed on first line palliative chemotherapy for advanced, unresectable, or metastatic pancreatic cancer.\n* Patients with active co-morbidities that would prevent or limit their participation in the exercise intervention\n* Age below 18 years old\n* No histological or cytological diagnosis of mesothelioma or pancreatic cancer.\n* ECOG Performance status of 2 or more\n* Unable to provide informed consent",{"count":69,"type":21},[72],"The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Patients will attend the AWRC for a supervised exercise session once a week to include aerobic exercise along with an unsupervised weekly exercise session for 3 months. Blood samples will be collected at baseline and then monthly for 3 months, pre and post the supervised exercise session. Cytokine, myokine and immune cell concentration will be analysed using cytokine bead-based multiplex immune assays and RNA-seq to full profile changes in gene and protein expression",[37,28],"NOT_YET_RECRUITING","2024-11-27",{"date":134,"type":52},"2024-12-03",{"date":136,"type":21},"2025-09-01",{"date":138,"type":21},"2027-03-01",{"name":140,"class":88},"Sheffield Teaching Hospitals NHS Foundation Trust",2]